Sydney, NSW – 7 June 2024
Organon ANZ today announced that Managing Director Nirelle Tolstoshev will depart the company on 28 June to take up a new opportunity outside of the organisation.
Nirelle has led Organon ANZ since inception three years ago, and previous to that, was with MSD for 21 years, starting as a Medical Representative in Adelaide, and progressing her career through Sales, Marketing and Business Unit management roles across a number of portfolios.
“Nirelle is known for her passion, personal ‘People First’ approach in managing an incredibly dynamic team, as well as for her innovative thinking to support our founders and the business to grow, said Andreas Daugaard Jørgensen, Managing Director, Asia Pacific.
“Nirelle has an incredible reputation as an authentic and highly skilled business leader with deep expertise in the healthcare environment. She is recognised as a champion for women in science. I am proud that Nirelle’s growth and experience at Organon has led to new opportunities for her, while she was building a strong foundation for the continued growth and impact of Organon in Australia and New Zealand, Andreas continued.
Organon will initiate the search for a new lead of the operations in Australia and New Zealand.
You can access further information about Organon Australia at https://www.organon.com/australia/ and connect with us on LinkedIn.
About Organon
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialise their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.
Copyright © (2024) Organon group of companies. All rights reserved.
Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. First issued June 2024.